Posted by Michael Wonder on 06 Dec 2024
Rigel announces R289 granted fast track designation by the FDA for lower risk myelodysplastic syndrome
2 December 2024 - Rigel Pharmaceuticals today announced that the US FDA has granted fast track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower risk myelodysplastic syndrome.
R2891, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with LR-MDS who are relapsed or refractory to prior therapies.
